AbbVie (ABBV) EBITDA Margin Growth (3y) (2015 - 2026)
AbbVie (ABBV) EBITDA Margin Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.32 Bn | 632.56 Bn | 17.26 Bn | 120.00 |
| 2 | AbbVie | 470.11 Bn | 463.54 Bn | 12.70 Bn | 531.00 |
| 3 | Merck | 376.14 Bn | 369.00 Bn | 12.21 Bn | 3,082.00 |
| 4 | Novartis Ag | 303.26 Bn | 295.57 Bn | 11.24 Bn | 842.00 |
| 5 | Astrazeneca | 257.39 Bn | 252.49 Bn | 12.86 Bn | -95.00 |
| 6 | Amgen | 236.59 Bn | 222.60 Bn | 7.24 Bn | -347.00 |
| 7 | Gilead Sciences | 181.91 Bn | 178.73 Bn | 6.22 Bn | -15,844.00 |
| 8 | Pfizer | 159.26 Bn | 147.57 Bn | 10.94 Bn | 20,333.00 |
| 9 | Gsk | 106.16 Bn | 101.99 Bn | 8.24 Bn | -2,411.00 |
| 10 | Sanofi | 55.11 Bn | 47.73 Bn | 10.79 Bn | 471.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 531.00 |
| Mar 31, 2026 | 395.00 |
| Dec 31, 2025 | -904.00 |
| Sep 30, 2025 | -1,901.00 |
| Jun 30, 2025 | 914.00 |
| Mar 31, 2025 | -687.00 |
| Dec 31, 2024 | -4,395.00 |
| Sep 30, 2024 | -353.00 |
| Jun 30, 2024 | -417.00 |
| Mar 31, 2024 | -881.00 |
| Dec 31, 2023 | -474.00 |
| Sep 30, 2023 | -885.00 |
| Jun 30, 2023 | 2,534.00 |
| Mar 31, 2023 | -1,916.00 |
| Dec 31, 2022 | -906.00 |
| Sep 30, 2022 | 21.00 |
| Jun 30, 2022 | -1,859.00 |
| Mar 31, 2022 | -361.00 |
| Dec 31, 2021 | 6,348.00 |
| Sep 30, 2021 | -833.00 |